Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach

Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach
CourtUnited States Court of Appeals for the District of Columbia Circuit
Full case nameAbigail Alliance for Better Access to Developmental Drugs, et al v. Andrew C. von Eschenbach
ArguedOctober 21, 2005
RearguedMarch 1, 2007
DecidedAugust 7, 2007
Citation(s)495 F.3d 695
Case history
Prior history2004 WL 3777340 (D.D.C. Aug. 30, 2004); 445 F.3d 470 (D.C. Cir. May 2, 2006).
Subsequent historyCert. denied, 552 U.S. 1159 (2008).
Court membership
Judge(s) sittingDouglas H. Ginsburg, David B. Sentelle, Karen L. Henderson, A. Raymond Randolph, Judith Ann Wilson Rogers, David S. Tatel, Merrick B. Garland, Janice Rogers Brown, Thomas B. Griffith, Brett Kavanaugh (en banc)
Case opinions
MajorityGriffith, joined by Sentelle, Henderson, Randolph, Tatel, Garland, Brown, Kavanaugh
DissentRogers, joined by Ginsburg

Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007),[1] cert denied, 552 U.S. 1159 (2008) was resolved in early 2008 when the Supreme Court of the United States declined to hear the appeal. Their refusal left standing the appellate court decision, which said that patients have no right to "a potentially toxic drug with no proven therapeutic benefit."[1][2]

  1. ^ a b Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007).
  2. ^ "No right to experimental drugs for dying patients: Supreme Court - Yahoo! News". Retrieved January 14, 2008. [dead link]

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search